RxDoctor Payments Data

David Tran, MD

Family Medicine · Largo, FLNPI 1811459928

Payments from drug & device makers

$6,396in general payments, 2019–2025

Across 249 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$901
  • AbbVie$878
  • Phathom Pharmaceuticals, Inc.$439
  • Lilly USA, LLC$387
  • Exact Sciences$322
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$6,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,396 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$60,060
Medicare patients
261
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$122,746
FarxigaDapagliflozin Propanediol77$105,452
JardianceEmpagliflozin42$65,544
EliquisApixaban34$38,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,785
JanuviaSitagliptin Phosphate12$17,101
TrulicityDulaglutide12$11,432
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,288
Doxepin Hcl11$4,915
Rosuvastatin Calcium267$3,927
Atorvastatin Calcium377$3,590
Omeprazole187$3,457
Levothyroxine Sodium331$3,421
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,722
SymbicortBudesonide/Formoterol Fumarate11$2,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$901$122,74697 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,013$116,369101 claims
Boehringer IngelheimJardiance$17$65,54442 claims
PfizerEliquis$264$38,71034 claims
GSKTrelegy Ellipta$302$22,78523 claims
MerckJanuvia$101$17,10112 claims
Lilly USA, LLCTrulicity$387$11,43212 claims
AbbVieSynthroid$878$1,31616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →